TAVR associated with improved kidney function in aortic stenosis patients: Study

USA: Chronic kidney disease (CKD) stage is more likely to improve than worsen in severe aortic stenosis patients with renal disease undergoing TAVR, according to findings from PARTNER trials. The findings of the study are published in the Journal of the American College of Cardiology.

There is poor understanding on the effect of transcatheter aortic valve replacement (TAVR) on kidney function stage in aortic stenosis patients. Robert J. Cubeddu, Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Weston, Weston, Florida, and colleagues hypothesized that in some patients, TAVR results in improved kidney function by alleviating cardiorenal syndrome.

The researchers aimed to assess change in CKD stage following TAVR, ideentify variables associated with pre- and post-TAVR estimated glomerular filtration rate (eGFR), and assess association of post-TAVR eGFR with mortality.

The study included 5,190 patients receiving TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) 1, 2, and PARTNER 2 S3 trials between April 2007 and October 2014. 

The researchers assessed Pre-TAVR and procedural variables associated with post-TAVR eGFR, change in CKD stage at ≤7 days post-TAVR, and association of post-TAVR eGFR on intermediate-term mortality. 

"In patients with severe aortic stenosis undergoing TAVR, even with baseline impaired eGFR, CKD stage is more likely to stay the same or improve than worsen," wrote the authors. "Aortic stenosis may contribute to cardiorenal syndrome that improves with TAVR."

Reference:

The study titled, "Impact of Transcatheter Aortic Valve Replacement on Severity of Chronic Kidney Disease," is published in the Journal of the American College of Cardiology.

DOI: https://www.jacc.org/doi/abs/10.1016/j.jacc.2020.07.048